All In Biotech

Drug Trial Radar · NCT01523301

Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

Double Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

Last checked: Nov 20, 2026Latest source record: Dec 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

380

Actual

Start

Apr 2012

Primary completion

Oct 2014

Study completion Oct 2014

Sponsor

Lead sponsor
UCB Korea Co., Ltd.UCB
Sponsor type
Industry
First posted
Feb 1, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to show superiority of Rotigotine over placebo on improvement of depressive symptoms in subjects with idiopathic Parkinson's disease.

Conditions

  • Idiopathic Parkinson's Disease

Interventions

  • RotigotineDrug

    Transdermal Patch Content: 2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2) * For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period * For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period

  • PlaceboDrug

    Transdermal Patch Size: 10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2 Subjects randomized to placebo received matching placebo patches

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to the End of Maintenance Period in the Score of the Hamilton Depression Scale (HAM-D)Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • 03

    Ansan, South Korea

  • 19

    Anyang, South Korea

  • 08

    Busan, South Korea

  • 26

    Busan, South Korea

  • 04

    Daegu, South Korea

  • 05

    Daegu, South Korea

  • 16

    Daejeon, South Korea

  • 28

    Goyang, South Korea

  • 24

    Gwangju, South Korea

  • 29

    Gwangju, South Korea

  • 11

    Gyeonggi-do, South Korea

  • 15

    Jinju, South Korea

  • 23

    Jungbuk, South Korea

  • 01

    Seoul, South Korea

  • 02

    Seoul, South Korea

  • 06

    Seoul, South Korea

  • 07

    Seoul, South Korea

  • 09

    Seoul, South Korea

  • 10

    Seoul, South Korea

  • 12

    Seoul, South Korea

  • 13

    Seoul, South Korea

  • 14

    Seoul, South Korea

  • 17

    Seoul, South Korea

  • 18

    Seoul, South Korea

  • 20

    Seoul, South Korea

  • 21

    Seoul, South Korea

  • 22

    Seoul, South Korea

  • 27

    Seoul, South Korea

  • 25

    Yangsan, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.